DGIdb - EPOETIN BETA Drug Record

EPOETIN BETA chembl:CHEMBL2109092 Approved

Alternate Names:

RECORMON S 1000
NEORECORMON 5000
NEORECORMON 2000
NEORECORMON 20000
NEORECORMON 4000
MAROGEN
RECORMON S 2000
RECORMON S 10000
NEORECORMON 6000
NEORECORMON 500
NEORECORMON 10000
NEORECORMON 3000
RECORMON 5000
NEORECORMON 1000
EPOCH
RECORMON 2000
RECORMON S 5000
NEORECORMON
RECORMON 10000
BM 06.019
ERYTHROPOIETIN
NEORECORMON 30000
EPOETIN BETA
RECORMON 1000

Drug Info:

Drug Indications	for treatment of stroke
Drug Indications	for treatment of anemia
FDA Approval	approved
Drug Class	protein
Drug Indications	erythropoietic agent
Drug Categories	hematinics
Drug Categories	erythropoietin, genetics
Drug Categories	increased erythroid cell production

(1 More Sources)

Publications:

Genc et al., 2006, Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage., Med. Hypotheses
LaMontagne et al., 2006, Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models., Mol. Cancer Ther.
Kokhaei et al., 2007, Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies., Clin. Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Ozüyaman et al., 2006, Adenosine produced via the CD73/ecto-5'-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight., Pflugers Arch.
Broxmeyer et al., 1991, CD45 cell surface antigens are linked to stimulation of early human myeloid progenitor cells by interleukin 3 (IL-3), granulocyte/macrophage colony-stimulating factor (GM-CSF), a GM-CSF/IL-3 fusion protein, and mast cell growth factor (a c-kit ligand)., J. Exp. Med.
Viviani et al., 2005, Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor., J. Neurochem.
Tsabouri et al., 2004, Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs., J. Exp. Clin. Cancer Res.
Hsieh et al., 2000, Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase., Blood
Papavasiliou et al., 2006, PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin., Nephrol. Dial. Transplant.
Bellizzi et al., 1997, Fetal proteins and chronic treatment with low-dose erythropoietin., J. Lab. Clin. Med.
Gündüz et al., 1999, Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis., Adv Perit Dial
Darley et al., 1997, Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells., J. Exp. Med.
Shan et al., 1999, Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin., Blood
Sturm et al., 2005, Recombinant human erythropoietin: effects on frataxin expression in vitro., Eur. J. Clin. Invest.

EPOETIN BETA EPOR

Interaction Score: 3.04

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Details of the Assay for Interaction Assay performed using recombinant human EPO

Specific Action of the Ligand Agonist

Endogenous Drug? True

PMIDs:
16505108 17575216 11752352

Sources:
DrugBank TdgClinicalTrial GuideToPharmacology
EPOETIN BETA PLA2G7

Interaction Score: 2.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16421163

Sources:
NCI
EPOETIN BETA FXN

Interaction Score: 2.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16269021

Sources:
NCI
EPOETIN BETA PLAT

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10682118

Sources:
NCI
EPOETIN BETA GSTT1

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15595630

Sources:
NCI
EPOETIN BETA AFP

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9016855

Sources:
NCI
EPOETIN BETA CDKN1B

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11023508

Sources:
NCI
EPOETIN BETA PTPRC

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1713254

Sources:
NCI
EPOETIN BETA NT5E

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16468051

Sources:
NCI
EPOETIN BETA CDKN1A

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11023508

Sources:
NCI
EPOETIN BETA HRAS

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9104820

Sources:
NCI
EPOETIN BETA BDNF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15816864

Sources:
NCI
EPOETIN BETA MAPK14

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10590051

Sources:
NCI
EPOETIN BETA NFE2L2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16707229

Sources:
NCI

DrugBank: DB00016

Version: 5.1.7

Alternate Names:

ERYTHROPOIETIN DrugBank Drug Name

11096-26-7 CAS Number

Abseamed Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Categories amino acids, peptides, and proteins

Publications:

Kokhaei et al., 2007, Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies., Clin. Cancer Res.

LaMontagne et al., 2006, Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models., Mol. Cancer Ther.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

GuideToPharmacology: 178101620
- Version: 29-September-2020
Alternate Names:

EPO Gene Symbol (for Endogenous Peptides)

ERYTHROPOIETIN GuideToPharmacology Ligand Name

Drug Info:

Name of the Ligand Species (if a Peptide) Human

Publications:
TdgClinicalTrial: ERYTHROPOIETIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications erythropoietic agent

Drug Class protein

FDA Approval approved

Publications:

NCI: ERYTHROPOIETIN

Version: 14-September-2017

Alternate Names:

C477 NCI drug code

Drug Info:

Publications:

Hsieh et al., 2000, Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase., Blood

Gündüz et al., 1999, Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis., Adv Perit Dial

Bellizzi et al., 1997, Fetal proteins and chronic treatment with low-dose erythropoietin., J. Lab. Clin. Med.

ChemblDrugs: chembl:CHEMBL2109092
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Details of the Assay for Interaction	Assay performed using recombinant human EPO
Specific Action of the Ligand	Agonist
Endogenous Drug?	True

ERYTHROPOIETIN	DrugBank Drug Name
11096-26-7	CAS Number
Abseamed	Drug Brand

Drug Type	biotech
Drug Groups	approved
Drug Categories	amino acids, peptides, and proteins

EPO	Gene Symbol (for Endogenous Peptides)
ERYTHROPOIETIN	GuideToPharmacology Ligand Name

EPOETIN BETA Drug Record

EPOETIN BETA chembl:CHEMBL2109092 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Details of the Assay for Interaction Assay performed using recombinant human EPO Specific Action of the Ligand Agonist Endogenous Drug? True

PMIDs: 16505108 17575216 11752352

Sources: DrugBank TdgClinicalTrial GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16421163

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16269021

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10682118

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15595630

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9016855

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11023508

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1713254

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16468051

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11023508

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9104820

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15816864

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10590051

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16707229

Sources: NCI

DrugBank: DB00016

Alternate Names: ERYTHROPOIETIN DrugBank Drug Name 11096-26-7 CAS Number Abseamed Drug Brand

Drug Info: Drug Type biotech Drug Groups approved Drug Categories amino acids, peptides, and proteins

GuideToPharmacology: 178101620

Alternate Names: EPO Gene Symbol (for Endogenous Peptides) ERYTHROPOIETIN GuideToPharmacology Ligand Name

Drug Info: Name of the Ligand Species (if a Peptide) Human

Publications:

TdgClinicalTrial: ERYTHROPOIETIN

Alternate Names:

Drug Info: Drug Indications erythropoietic agent Drug Class protein FDA Approval approved

Publications:

NCI: ERYTHROPOIETIN

Alternate Names: C477 NCI drug code

Drug Info:

ChemblDrugs: chembl:CHEMBL2109092

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Details of the Assay for Interaction Assay performed using recombinant human EPO

Specific Action of the Ligand Agonist

Endogenous Drug? True

PMIDs:
16505108 17575216 11752352

Sources:
DrugBank TdgClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
16421163

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16269021

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10682118

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15595630

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9016855

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11023508

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1713254

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16468051

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11023508

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9104820

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15816864

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10590051

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16707229

Sources:
NCI

Alternate Names:

ERYTHROPOIETIN DrugBank Drug Name

11096-26-7 CAS Number

Abseamed Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Categories amino acids, peptides, and proteins

Alternate Names:

EPO Gene Symbol (for Endogenous Peptides)

ERYTHROPOIETIN GuideToPharmacology Ligand Name

Drug Info:

Name of the Ligand Species (if a Peptide) Human

Drug Info:

Drug Indications erythropoietic agent

Drug Class protein

FDA Approval approved

Alternate Names:

C477 NCI drug code